menu
    • menu

    Company profile for Orexo

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies. Launched products Zubsolv® is a product for the maintenance treatment of opioid dependence. On July 3, 2013, the product was approved by the U.S. Food and Drug Administration, FDA and on September...
    Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies. Launched products Zubsolv® is a product for the maintenance treatment of opioid dependence. On July 3, 2013, the product was approved by the U.S. Food and Drug Administration, FDA and on September 16, 2013, the product was launched on the US market.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OrexoSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    P.O. Box 303 751 05 Uppsala, Sweden
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://orexo.com/start/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Orexo Us Secures $8m Barda Funding For Ox390 Development
    Orexo Us Secures $8m Barda Funding For Ox390 Development

    30 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-30/orexo-us-awarded-usd-8-million-by-barda-for-ox390-development-partnership

    PHARMAWEB
    30 Sep 2025
    Share Share
    Orexo Secures Landmark Patent Victory in US Court
    Orexo Secures Landmark Patent Victory in US Court

    30 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/seminar-ip-that-matters---behind-orexos-milestone-patent-win-at-the-us-court-302541994.html

    PR NEWSWIRE
    30 Aug 2025
    Share Share
    Orexo to present clinical data for OX640 at the EAACI Congress
    Orexo to present clinical data for OX640 at the EAACI Congress

    02 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orexo-to-present-clinical-data-for-ox640-at-the-eaaci-congress-302470705.html

    PR NEWSWIRE
    02 Jun 2025
    Share Share
    Orexo reports positive data for AmorphOX intranasal Vaccine
    Orexo reports positive data for AmorphOX intranasal Vaccine

    10 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orexo-announces-positive-data-for-powder-based-intranasal-vaccine-formulated-with-the-amorphox-technology-302425436.html

    PR NEWSWIRE
    10 Apr 2025
    Share Share
    Orexo Reports Positive Data for OX640 in Allergic Rhinitis Study
    Orexo Reports Positive Data for OX640 in Allergic Rhinitis Study

    10 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orexo-announces-positive-topline-data-from-clinical-study-of-ox640-in-subjects-with-and-without-allergic-rhinitis-302347970.html

    PR NEWSWIRE
    10 Jan 2025
    Share Share
    Orexo Enters Collaboration with Abera for Nasal Powder Vaccines
    Orexo Enters Collaboration with Abera for Nasal Powder Vaccines

    17 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orexo-enters-into-collaboration-with-abera-to-develop-nasal-powder-vaccines-based-on-the-amorphox-technology-302333487.html

    PR NEWSWIRE
    17 Dec 2024
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search